BiotechTube

Daptomycin + Standard of Care (SOC)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Skin Diseases, Infectious

Conditions

Skin Diseases, Infectious

Trial Timeline

Jul 23, 2008 → Oct 11, 2013

NCT ID
NCT00711802

About Daptomycin + Standard of Care (SOC)

Daptomycin + Standard of Care (SOC) is a approved stage product being developed by Merck for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00711802. Target conditions include Skin Diseases, Infectious.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00711802ApprovedCompleted

Competing Products

20 competing products in Skin Diseases, Infectious

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test productSun PharmaceuticalPhase 1
33
LY3041658 + PlaceboEli LillyPhase 1
33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulationSumitomo PharmaPhase 1
33
levofloxacinJohnson & JohnsonPhase 2/3
65
Moisturizer A, F#9155-005Johnson & JohnsonPre-clinical
23
levofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
LevofloxacinJohnson & JohnsonPhase 3
77
CeftobiproleJohnson & JohnsonPhase 1
33
Levodopa-carbidopa intestinal gelAbbViePhase 3
77
IressaAstraZenecaPhase 2
52
Daptomycin + VancomycinAstraZenecaPhase 3
77
SarizotanMerckPre-clinical
23
Pembrolizumab + EDP1503MerckPhase 2
52
testosterone gel + Comparator: placeboMerckPhase 1
33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)MerckPhase 2/3
65
Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85